The EFHD1 Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from HT29 human colorectal adenocarcinoma epithelial cells, with targeted disruption of the EFHD1 gene. This heterogeneous pool of loss-of-function mutants provides a robust tool for studying calcium-dependent signaling, apoptosis, and actin dynamics, circumventing the clonal selection artifacts typical of single-cell-derived knockout lines. The polyclonal format ensures representation of diverse genetic backgrounds, enabling more broadly applicable functional studies.
The HT29 cell line was established in 1964 from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. These adherent epithelial cells retain intestinal characteristics such as microvilli, mucin secretion, and tight junction formation. HT29 cells harbor key mutations in APC, TP53, and KRAS, which are frequently observed in colorectal cancer, making them an ideal model for investigating tumorigenesis, metastasis, and drug responses. Their well-characterized signaling networks facilitate dissection of oncogenic pathways in a physiologically relevant epithelial context.
EFHD1 is an EF-hand calcium-binding protein that acts as a molecular transducer of calcium signals into apoptotic and cytoskeletal responses. Activated downstream of calcium influx, EFHD1 interacts directly with calcium ions, actin, Bcl-2 family members, and NF-??B pathway components. Its activity is regulated by upstream signals from NF-??B, p53, and pro-inflammatory cytokines, while it influences downstream targets including the actin cytoskeleton, caspases, and NF-??B transcriptional complexes. Through these interactions, EFHD1 promotes cell survival under stress, modulates mitochondrial apoptosis, and facilitates actin remodeling required for cell migration and immune signaling.
In the HT29 colorectal adenocarcinoma background, EFHD1 knockout disrupts the orchestration of calcium-dependent apoptosis and actin dynamics, processes deeply intertwined with malignant progression. This model permits detailed investigation of how EFHD1 coordinates Bcl-2 family protein regulation, caspase activation, and cytoskeletal reorganization in an epithelial cancer context. Moreover, it enables study of the crosstalk between calcium-mediated pathways and innate immune signaling, particularly via NF-??B, providing insights relevant to colorectal cancer and inflammatory disorders.
Research applications include quantitative apoptosis analysis by flow cytometry and western blotting for cleaved caspases and Bcl-2 members, actin visualization via immunofluorescence, migration/invasion assays, drug sensitivity profiling using colony formation and viability tests, and mitochondrial function studies with calcium imaging. These assays support investigations into calcium-dependent cell death, metastatic potential, therapy resistance, and immune signaling. For additional technical details, please contact Ascent Research.
